- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Socioeconomic Implications of CSCC and BCC
Experts explore the socioeconomic impact of CSCC and BCC, and which late-stage patients will derive the greatest benefit from hedgehog inhibitors, immunotherapies, and other emerging treatments.
EP: 1.Prevalence of Cutaneous Squamous Cell Carcinoma (CSCC) & Basal Cell Carcinoma (BCC)
EP: 2.Immunotherapy Landscape in cSCC and BCC
EP: 3.Immunotherapy and Radiation Therapy in cSCC and BCC
EP: 4.Immunotherapy Barriers: Multidisciplinary Approach in cSCC and BCC
EP: 5.Coordination of Care: Interdisciplinary Immunotherapy Challenges in Nonmelanoma Skin Cancers
EP: 6.Multidisciplinary Collaboration: Best Practices for CSCC and BCC Management
EP: 7.Dermatologists and Immunotherapy: Managing Patient Expectations
EP: 8.Monitoring Immunotherapy Toxicities in CSCC and BCC
EP: 9.Staging Disease and Risk Stratification in CSCC and BCC
EP: 10.Targeted Therapy: Hedgehog Inhibitors in BCC
EP: 11.Socioeconomic Implications of CSCC and BCC
EP: 12.Immunosuppression in CSCC and BCC Treatment
EP: 13.Updates in Therapeutics for Nonmelanoma Skin Cancers
EP: 14.Concluding Thoughts on the Future of CSCC and BCC Care
This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; Christopher Barker, MD; Omid Hamid, MD; Vishal Patel, MD; and Catherine Pisano, MD.
Pisano noted that patients presenting with advanced cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) often have limited health care access and resources. While immunotherapy dramatically benefits these individuals, high out-of-pocket costs can be prohibitive without insurance coverage or patient assistance programs. She advised avoiding hedgehog inhibitors for malnourished and/or economically disadvantaged BCC patients given the additional toxicity concerns that may worsen nutritional status. Hamid emphasized the importance of corporate-sponsored patient assistance programs and co-pay support in accessing therapies. He also stressed educating patients on the realities of systemic treatment, as many view skin cancers as easily resolved by surgery alone. The extensive monitoring and potential adverse effects associated with targeted and immune-based medications differs greatly from this perception.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More
